Prospera Financial Services Inc Buys New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Prospera Financial Services Inc purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,033 shares of the medical research company’s stock, valued at approximately $245,000.

Other large investors also recently modified their holdings of the company. Canada Pension Plan Investment Board grew its stake in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares in the last quarter. Impax Asset Management Group plc increased its holdings in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Legal & General Group Plc raised its position in shares of IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after acquiring an additional 11,715 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in IQVIA by 5.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock valued at $253,125,000 after purchasing an additional 60,827 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Robert W. Baird cut their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Morgan Stanley decreased their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Trading Up 1.1 %

Shares of IQVIA stock opened at $204.02 on Tuesday. The firm has a market cap of $37.03 billion, a price-to-earnings ratio of 26.77, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company’s 50-day simple moving average is $221.96 and its 200-day simple moving average is $226.98. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.